Drug and biomarker tissue levels in a randomized presurgical trial on exemestane alternative schedules.
J Natl Cancer Inst
; 2024 Aug 07.
Article
in En
| MEDLINE
| ID: mdl-39110531
ABSTRACT
The drug's activity at the target tissue could help to define the minimal effective dose to promote cancer preventive therapy. Here we present exemestane and sex hormone concentrations within breast tissue from a pre-surgical study of alternative exemestane schedules. Postmenopausal women candidate for breast surgery for estrogen receptor-positive breast cancer were randomized to exemestane 25 mg once daily (QD), 25 mg three times/week (TIW), or 25 mg per/week (QW) for 4-6 weeks before surgery. Drug and sex hormones were analyzed from homogenized frozen tissue using a QTRAP 6500+ LC-MS/MS System. Tissue drug concentrations were detectable only in the QD arm with higher concentrations in non-malignant tissue. Estradiol was nearly suppressed in all groups in the non-malignant tissue (QD vs TIW p = .364 and QD vs QW p = .693). In contrast, a dose-response trend was observed in cancer tissue. Based on estradiol suppression in non-malignant tissue, lower exemestane schedules should be explored for breast cancer preventive therapy.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
J Natl Cancer Inst
Year:
2024
Document type:
Article
Affiliation country:
Italy